Managing the Changing Faces of HBV Infection in HIV

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > Peters > Slides

Managing the Changing Faces of HBV Infection in HIV

Slide Presentation
March 8, 2006
Marion Peters, MD

Click on slide thumbnails to view full-sized image.

Download the entire set of PowerPoint slides

Slide 1.

Managing the changing faces of HBV infection in HIV

Slide 1.

HIV Coinfection Increases the Risk of ESLD Due to HBV

Slide 2.

Managing the changing faces of HBV infection in HIV

Slide 3.

Managing the changing faces of HBV infection in HIV

Slide 4.

Outcome of HBV by Age of Acquisition- immune status

Slide 5.

Geographic Distribution of Chronic HBV Infection

Slide 6.

Risk Factors for Acute Hepatitis B 1990-2000, United States

Slide 7.

Overlapping HBV & HIV Epidemics

Slide 8.

HBV Epidemiology

Slide 9.

Hepatitis B Disease Progression

Slide 10.

Natural History of Chronic HBV Infection

Slide 11.

Managing the changing faces of HBV infection in HIV

Slide 12.

HBV

Slide 13.

HBeAg and precore mutation

Slide 14.

HBeAg and precore mutation

Slide 15.

Hepatitis B Serologies

Slide 16.

Managing the changing faces of HBV infection in HIV

Slide 17.

Initial evaluation of a person with newly identified HBV in HIV infection

Slide 18.

HBV is a dynamic disease

Slide 19.

HBV vaccine response rate

Slide 20.

Managing the changing faces of HBV infection in HIV

Slide 21.

Hepatitis B Serologies

Slide 22.

Anti-HBcAg Alone: HBsAg-, HBsAb-

Slide 23.

HBV- HIV Co-infection

Slide 24.

Occult infection

Slide 25.

Managing the changing faces of HBV infection in HIV

Slide 26.

Viral Life Cycle

Slide 27.

Viral Life Cycle- latent HBV

Slide 28.

Clinical Treatment Endpoints in Compensated CHB

Slide 29.

HBV Control

Slide 30.

? Therapy in acute HBV

Slide 31.

HBV- HIV therapy

Slide 32.

HBV and HIV results with ADV

Slide 33.

HBV- HIV therapy

Slide 34.

HBV and HIV therapies

Slide 35.

HBV treatment decision algorithm

Slide 36.

Preferred anti-HBV agents in drug-naive HBV/HIV coinfected patients candidates for HBV therapy

Slide 37.

HIV / HBV treatment

Slide 38.

Monitoring HBV

Slide 39.

Managing the changing faces of HBV infection in HIV

Slide 40.

GLOBE: Early HBV DNA Levels and Year 1 Outcomes With Telbivudine

Slide 41.

Monitor on therapy

Slide 42.

Managing the changing faces of HBV infection in HIV

Slide 43.

Chronic HBV HIV

Slide 44.

Liver Disease in HIV Infection

Slide 45.

HBV HIV and HAART: abnormal LFTs

Slide 46.

Managing the changing faces of HBV infection in HIV

Slide 47.

Resistance Rates in Naive Patients Treated with LMV, ADV or LdT

Slide 48.

Month 6 HBV DNA Suppression Predicts Risk of Subsequent Lamivudine Resistance

Slide 49.

Week 48 HBV DNA Suppression Predicts Risk of Subsequent Adefovir Resistance

Slide 50.

HBV HIV resistance

Slide 51.

Impact on natural history of each

Slide 52.

Impact on natural history of each

Slide 53.

HBV-HIV Summary

Slide 54.